{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:26:49Z","timestamp":1788265609032,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbes and Infection"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.micinf.2025.105546","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:39:16Z","timestamp":1752604756000},"page":"105546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic strategies to combat Staphylococcus aureus infections in cystic fibrosis"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-132X","authenticated-orcid":false,"given":"Aygun","family":"Israyilova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-4409","authenticated-orcid":false,"given":"Gabriele","family":"Trespidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-1655","authenticated-orcid":false,"given":"Viola Camilla","family":"Scoffone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-2275","authenticated-orcid":false,"given":"Silvia","family":"Buroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micinf.2025.105546_bib1","series-title":"ECFSPR annual report 2022","author":"Zolin","year":"2024"},{"key":"10.1016\/j.micinf.2025.105546_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Investig"},{"key":"10.1016\/j.micinf.2025.105546_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/17476348.2015.995640","article-title":"The problems of antibiotic resistance in cystic fibrosis and solutions","volume":"9","author":"L\u00f3pez-Causap\u00e9","year":"2015","journal-title":"Expet Rev Respir Med"},{"key":"10.1016\/j.micinf.2025.105546_bib4","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/ppul.24139","article-title":"Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis","volume":"53","author":"Akil","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.micinf.2025.105546_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jgar.2023.05.006","article-title":"Prevalence of antibiotic resistance of Staphylococcus aureus in cystic fibrosis infection: a systematic review and meta-analysis","volume":"36","author":"Xu","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.micinf.2025.105546_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jcf.2017.12.002","article-title":"The association between Staphylococcus aureus and subsequent bronchiectasis in children with cystic fibrosis","volume":"17","author":"Caudri","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.micinf.2025.105546_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1513\/AnnalsATS.201705-376OC","article-title":"Early respiratory bacterial detection and antistaphylococcal antibiotic prophylaxis in young children with cystic fibrosis","volume":"15","author":"Hurley","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.micinf.2025.105546_bib8","article-title":"Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis","volume":"7","author":"Ahmed","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.micinf.2025.105546_bib10","article-title":"Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","volume":"12","author":"Lo","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.micinf.2025.105546_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/antibiotics12030484","article-title":"Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis","volume":"12","author":"Li","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.micinf.2025.105546_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/acsinfecdis.3c00696","article-title":"Synergistic augmentation of beta-lactams: exploring quinoline-derived amphipathic small molecules as antimicrobial potentiators against methicillin-resistant Staphylococcus aureus","volume":"10","author":"Ghosh","year":"2024","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.micinf.2025.105546_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04083-22","article-title":"Mutual effects of single and combined CFTR modulators and bacterial infection in cystic fibrosis","volume":"11","author":"Cigana","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.micinf.2025.105546_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03148-21","article-title":"Combining ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections","volume":"12","author":"Durfey","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.micinf.2025.105546_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: the SIMPLIFY clinical trial study design","volume":"18","author":"Mayer-Hamblett","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.micinf.2025.105546_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jgar.2021.12.008","article-title":"Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adults","volume":"28","author":"Esquivel","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.micinf.2025.105546_bib17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2533\/chimia.2023.230","article-title":"Clinically approved antibiotics from 2010 to 2022","volume":"77","author":"Jung","year":"2023","journal-title":"Chimia"},{"key":"10.1016\/j.micinf.2025.105546_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01914-19","article-title":"Pharmacokinetics of telavancin in adult patients with cystic fibrosis during acute pulmonary exacerbation","volume":"64","author":"Kidd","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.micinf.2025.105546_bib19","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/s41467-025-58061-5","article-title":"Bacterial cell wall-specific nanomedicine for the elimination of Staphylococcus aureus and Pseudomonas aeruginosa through electron-mechanical intervention","volume":"16","author":"You","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.micinf.2025.105546_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01140-20","article-title":"The neutrally charged diarylurea compound PQ401 kills antibiotic-resistant and antibiotic-tolerant Staphylococcus aureus","volume":"11","author":"Kim","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.micinf.2025.105546_bib21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1021\/acsinfecdis.4c01045","article-title":"Identification of a new FtsZ inhibitor by virtual screening, mechanistic insights, and structure-activity relationship analyses","volume":"11","author":"Sci\u00f2","year":"2025","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.micinf.2025.105546_bib22","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/pathogens10070886","article-title":"Antistaphylococcal activity of the FtsZ inhibitor C109","volume":"10","author":"Trespidi","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.micinf.2025.105546_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/acsinfecdis.1c00409","article-title":"Variable susceptibility to gallium compounds of major cystic fibrosis pathogens","volume":"8","author":"Visaggio","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.micinf.2025.105546_bib24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.abd8377","article-title":"Inhibitors of bacterial H2S biogenesis targeting antibiotic resistance and tolerance","volume":"372","author":"Shatalin","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.micinf.2025.105546_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3390\/antibiotics14040402","article-title":"Repurposing high-throughput screening reveals unconventional drugs with antimicrobial and antibiofilm potential against methicillin-resistant Staphylococcus aureus from a cystic fibrosis patient","volume":"14","author":"Pompilio","year":"2025","journal-title":"Antibiotics"},{"key":"10.1016\/j.micinf.2025.105546_bib26","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.3390\/ijms24054532","article-title":"Cytotoxic and bactericidal effects of inhalable ciprofloxacin-loaded Poly(2-ethyl-2-oxazoline) nanoparticles with traces of zinc oxide","volume":"24","author":"Sabuj","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.micinf.2025.105546_bib27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jconrel.2024.08.029","article-title":"Antibiotic-loaded nanoparticles for the treatment of intracellular methicillin-resistant Staphylococcus aureus infections: in vitro and in vivo efficacy of a novel antibiotic","volume":"374","author":"Costabile","year":"2024","journal-title":"J Contr Release"},{"key":"10.1016\/j.micinf.2025.105546_bib28","article-title":"Positioning the preventive potential of microbiome treatments for cystic fibrosis in the context of current therapies","volume":"16","author":"Cauwenberghs","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.micinf.2025.105546_bib29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.chom.2023.04.004","article-title":"Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections","volume":"31","author":"Buckley","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.micinf.2025.105546_bib30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/JCM.00255-09","article-title":"Prevalence of community-associated methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis","volume":"47","author":"Goodrich","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.micinf.2025.105546_bib31","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.22815","article-title":"STAR-CF study team. Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis","volume":"49","author":"Champion","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.micinf.2025.105546_bib32","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1378\/chest.07-2437","article-title":"Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus","volume":"133","author":"Glikman","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.micinf.2025.105546_bib33","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/antibiotics13111046","article-title":"Potential therapeutic targets for combination antibody therapy against Staphylococcus aureus infections","volume":"13","author":"Ke","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.micinf.2025.105546_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1275940","article-title":"MEK1\/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection","volume":"14","author":"De","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.micinf.2025.105546_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/pathogens13010076","article-title":"Biofilm producing methicillin-resistant Staphylococcus aureus (MRSA) infections in humans: clinical implications and management","volume":"13","author":"Kaushik","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.micinf.2025.105546_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.750489","article-title":"Biofilm formation in methicillin-resistant Staphylococcus aureus isolated in cystic fibrosis patients is strain-dependent and differentially influenced by antibiotics","volume":"12","author":"Boudet","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.micinf.2025.105546_bib37","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/acsinfecdis.9b00016","article-title":"Antibiofilm efficacy of nitric oxide-releasing alginates against cystic fibrosis bacterial pathogens","volume":"5","author":"Ahonen","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.micinf.2025.105546_bib38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3389\/fmicb.2018.01349","article-title":"Electrochemically synthesized silver nanoparticles are active against planktonic and biofilm cells of Pseudomonas aeruginosa and other cystic fibrosis-associated bacterial pathogens","volume":"9","author":"Pompilio","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.micinf.2025.105546_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/mmbr.00037-22","article-title":"Antimicrobial peptides and small molecules targeting the cell membrane of Staphylococcus aureus","volume":"87","author":"Ganesan","year":"2023","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.micinf.2025.105546_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01596-23","article-title":"A novel small-molecule compound S-342-3 effectively inhibits the biofilm formation of Staphylococcus aureus","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.micinf.2025.105546_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay9597","article-title":"A new coumarin compound DCH combats methicillin-resistant Staphylococcus aureus biofilm by targeting arginine repressor","volume":"6","author":"Qu","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.micinf.2025.105546_bib42","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3390\/antibiotics12121706","article-title":"In vitro activities of oxazolidinone antibiotics alone and in combination with C-TEMPO against methicillin-resistant Staphylococcus aureus biofilms","volume":"12","author":"Ndukwe","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.micinf.2025.105546_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203621","article-title":"Enhanced biofilm prevention activity of a SPLUNC1-derived antimicrobial peptide against Staphylococcus aureus","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.micinf.2025.105546_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2022.127152","article-title":"Antimicrobial peptides for tackling cystic fibrosis related bacterial infections: a review","volume":"263","author":"Bugli","year":"2022","journal-title":"Microbiol Res"},{"key":"10.1016\/j.micinf.2025.105546_bib45","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3389\/fimmu.2020.01198","article-title":"Expression and roles of antimicrobial peptides in innate defense of airway mucosa: potential implication in cystic fibrosis","volume":"11","author":"Geitani","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.micinf.2025.105546_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2017.04.014","article-title":"Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens","volume":"50","author":"Payne","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.micinf.2025.105546_bib47","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2217\/fmb.09.87","article-title":"The vitamin D\u2013antimicrobial peptide pathway and its role in protection against infection","volume":"4","author":"Gombart","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.micinf.2025.105546_bib48","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1172\/JCI30142","article-title":"Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D\u2013dependent mechanism","volume":"117","author":"Schauber","year":"2007","journal-title":"J Clin Investig"},{"key":"10.1016\/j.micinf.2025.105546_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01821-19","article-title":"The ancestral N-Terminal domain of big defensins drives bacterially triggered assembly into antimicrobial nanonets","volume":"10","author":"Loth","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.micinf.2025.105546_bib50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/21505594.2016.1213475","article-title":"Activity of antimicrobial peptides, alone or combined with conventional antibiotics, against Staphylococcus aureus isolated from the airways of cystic fibrosis patients","volume":"8","author":"Garbacz","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.micinf.2025.105546_bib51","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1074\/jbc.273.6.3718","article-title":"Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37","volume":"273","author":"Johansson","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.micinf.2025.105546_bib52","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.bbamem.2006.03.030","article-title":"LL-37, the only human member of the cathelicidin family of antimicrobial peptides","volume":"1758","author":"D\u00fcrr","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.micinf.2025.105546_bib53","doi-asserted-by":"crossref","first-page":"9804","DOI":"10.1021\/bi050272k","article-title":"Structure\u2013activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity","volume":"44","author":"Kl\u00fcver","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.micinf.2025.105546_bib54","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.peptides.2003.07.025","article-title":"In vitro and in vivo antimicrobial activity of two \u03b1-helical cathelicidin peptides and of their synthetic analogs","volume":"24","author":"Benincasa","year":"2003","journal-title":"Peptides"},{"key":"10.1016\/j.micinf.2025.105546_bib55","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00726-016-2266-4","article-title":"In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections","volume":"48","author":"Mardirossian","year":"2016","journal-title":"Amino Acids"},{"key":"10.1016\/j.micinf.2025.105546_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/pep2.24207","article-title":"Introduction of cell-selectivity in bovine cathelicidin BMAP-28 by exchanging heptadic isoleucine with the adjacent proline at a non-heptadic position","volume":"113","author":"Azmi","year":"2021","journal-title":"Pept Sci"},{"key":"10.1016\/j.micinf.2025.105546_bib57","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jac\/dkf141","article-title":"Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use","volume":"50","author":"Pacor","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.micinf.2025.105546_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2180-12-145","article-title":"Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed \u03b1-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia","volume":"12","author":"Pompilio","year":"2012","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.micinf.2025.105546_bib59","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1462-5822.2004.00367.x","article-title":"Polysaccharide intercellular adhesin (pia) protects Staphylococcus epidermidis against major components of the human innate immune system","volume":"6","author":"Vuong","year":"2004","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.micinf.2025.105546_bib60","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/genes12101527","article-title":"Antibacterial peptides resistance in staphylococcus aureus: various mechanisms and the association with pathogenicity","volume":"12","author":"Kawada-Matsuo","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.micinf.2025.105546_bib61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/dkw381","article-title":"Antimicrobial peptide exposure selects for Staphylococcus aureus resistance to human defence peptides","volume":"72","author":"Kubicek-Sutherland","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.micinf.2025.105546_bib62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.30","article-title":"Emerging trends in oral delivery of peptide and protein drugs","volume":"20","author":"Mahato","year":"2003","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.micinf.2025.105546_bib63","first-page":"205","article-title":"Recent advances in protein and peptide drug delivery, res. J. Pharm. Dos","volume":"12","author":"Yadav","year":"2020","journal-title":"Forms Technol"},{"key":"10.1016\/j.micinf.2025.105546_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg5995","article-title":"Killing of Staphylococcus aureus persisters by a multitarget natural product chrysomycin A","volume":"9","author":"Jia","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.micinf.2025.105546_bib65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41429-019-0153-4","article-title":"Synthesis and antibiotic activity of novel acylated phloroglucinol compounds against methicillin-resistant Staphylococcus aureus","volume":"72","author":"Mittal","year":"2019","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.micinf.2025.105546_bib66","article-title":"Quercetin reduces the virulence of S. aureus by targeting ClpP to protect mice from MRSA-induced lethal pneumonia","volume":"27","author":"Jing","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.micinf.2025.105546_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.907314","article-title":"Bacteriophage therapy for Staphylococcus aureus infections: a review of animal models, treatments, and clinical trials","volume":"12","author":"Plumet","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.micinf.2025.105546_bib68","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1751-7915.2011.00259.x","article-title":"Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens","volume":"4","author":"Kvachadze","year":"2011","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.micinf.2025.105546_bib69","first-page":"1096","article-title":"Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients","volume":"13","author":"Bernab\u00e9u-Gimeno","year":"2024","journal-title":"M\u00e9d Sur"},{"key":"10.1016\/j.micinf.2025.105546_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107276","article-title":"Bacteriophages as potential antibiotic potentiators in cystic fibrosis: a new model to study the combination of antibiotics with a bacteriophage cocktail targeting dual species biofilms of Staphylococcus aureus and Pseudomonas aeruginosa","volume":"64","author":"Wang","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.micinf.2025.105546_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/mra.01047-24","article-title":"COMBAT study group, A near-complete genome of the uncultured Staphylococcus aureus phage COMBAT-CF_PAR1 isolated from the lungs of an infant with cystic fibrosis","volume":"13","author":"Agudelo-Romero","year":"2024","journal-title":"Microbiol Resour Announc"},{"key":"10.1016\/j.micinf.2025.105546_bib72","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/v14051061","article-title":"Understanding the mechanisms that drive phage resistance in staphylococci to prevent phage therapy failure","volume":"14","author":"Jurado","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.micinf.2025.105546_bib73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.copbio.2020.11.003","article-title":"Enhancing phage therapy through synthetic biology and genome engineering","volume":"68","author":"Lenneman","year":"2021","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.micinf.2025.105546_bib74","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1021\/acsinfecdis.0c00812","article-title":"Development of advanced chimeric endolysin to control multidrug-resistant Staphylococcus aureus through domain shuffling","volume":"13","author":"Lee","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.micinf.2025.105546_bib75","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1038\/s41467-024-49603-4","article-title":"Guiding antibiotics towards their target using bacteriophage proteins","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.micinf.2025.105546_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2024.116321","article-title":"Evaluation of mixed biofilm production by candida spp. and Staphylococcus aureus strains co-isolated from cystic fibrosis patients in northwest Algeria","volume":"109","author":"Gourari-Bouzouina","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.micinf.2025.105546_bib77","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1074\/jbc.M008557200","article-title":"Isolation and characterization of human \u03bc-Defensin-3, a novel human inducible peptide antibiotic","volume":"276","author":"Harder","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.micinf.2025.105546_bib78","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0888-7543(02)00034-4","article-title":"Distribution of new human beta-defensin genes clustered on chromosome 20 in functionally different segments of epididymis","volume":"81","author":"Rodr\u00edguez-Jim\u00e9nez","year":"2003","journal-title":"Genomics"}],"container-title":["Microbes and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1286457925000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1286457925000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:12:23Z","timestamp":1788264743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1286457925000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1286457925000784"],"URL":"https:\/\/doi.org\/10.1016\/j.micinf.2025.105546","relation":{},"ISSN":["1286-4579"],"issn-type":[{"value":"1286-4579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic strategies to combat Staphylococcus aureus infections in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Microbes and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micinf.2025.105546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Institut Pasteur. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105546"}}